Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCN-12
- Development stage
- Preclinical
- Lead developer
- Theriva Biologics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intracranial
01
Overview
**VCN-12** is a next-generation oncolytic adenovirus selected from Theriva Biologics' VCN-X discovery program and is derived from their lead clinical product VCN-01 (zabilugene almadenorepvec)[1][2][3][4]. VCN-12 is armed with additional transgenes engineered to improve tumor cell lysis, enhance tumor stroma degradation, and augment antitumor immune responses[1][2][3][4]. The drug is specifically designed as an antitumor agent with potential feasibility for intracranial administration in brain tumors[1][2][3][4]. Preclinical data suggest its mechanism of action may result in significant improvement in antitumor effects compared to earlier generations[1][2][3][4].
- Brand names
- VCN-12VCN12VCN 12
- Other names
- VCN-12VCN12VCN 12
02
Targets
RB1 (Retinoblastoma-associated Protein)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on VCN-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCN-12.